Development and characterization of a triple combination gene therapy vector inhibiting HIV-1 multiplication

Journal of Gene Medicine

Volumn 10, Issue 10, 2008, Pages 1059-1070

  Asparuhova, Maria B ^a   Barde, Isabelle ^b   Trono, Didier ^b   Schranz, Karin ^a   Schümperli, Daniel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

Cyclophilin A; Exon skipping; HIV; RNA interference; U7 snRNA; Viral infectivity factor

Indexed keywords

COMPLEMENTARY DNA; COMPLEMENTARY RNA; CYCLOPHILIN A; LENTIVIRUS VECTOR; REV PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SMALL NUCLEAR RNA; TRANSACTIVATOR PROTEIN; VIF PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DNA INTEGRATION; EXON; GENE CASSETTE; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS INHIBITION; VIRUS REPLICATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CD4-POSITIVE T-LYMPHOCYTES; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; PROMOTER REGIONS, GENETIC; RNA, ANTISENSE; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

EID: 58149189436     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1238     Document Type: Article

References (56)

1. Martinez-Picado J, DePasquale MP, Kartsonis N, et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. PNAS 2000; 97: 10948-10953.
2. ter Hofstede HJ, Burger DM, Koopmans PP. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity. Neth J Med 2003; 61: 393-403.
3. Baltimore D. Gene therapy. Intracellular immunization. Nature 1988; 335: 395-396.
4. Nielsen M, Pedersen F, Kjems J. Molecular strategies to inhibit HIV-1 replication. Retrovirology 2005; 2: 10.
5. Kohn DB, Bauer G, Rice CR, et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34+ cells from the bonemarrow of human immunodeficiency virus-1-infected children. Blood 1999; 94: 368-371.
6. Amado RG, Mitsuyasu RT, Rosenblatt JD, et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 2004; 15: 251-262.
7. Macpherson JL, Carr A, Cooper DA. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med 2005; 7: 552-564.
8. Gervaix A, Li X, Kraus G, et al. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol 1997; 71: 3048-3053.
9. Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909.
10. Barnor JS, Miyano-Kurosaki N, Yamaguchi K, et al. Lentiviral-mediated delivery of combined HIV-1 decoy TAR and Vif siRNA as a single RNA molecule that cleaves to inhibit HIV-1 in transduced cells. Nucleosides Nucleotides Nucleic Acids 2005; 24: 431-434.
11. ter Brake O, Konstantinova P, Ceylan M, et al. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 2006; 14: 883-892.
12. Anderson J, Li MJ, Palmer B, et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes - CCR5 ribozyme, tat-rev siRNA, and TAR decoy - in SCID-hu mouse-derived T cells. Mol Ther 2007; 15: 1182-1188.
13. Boden D, Pusch O, Ramratnam B. Overcoming HIV-1 resistance to RNA interference. Front Biosci 2007; 12: 3104-3116.
14. ter Brake o, t'Hooft K, Liu YP, et al. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 2008; 16: 557-564.
15. Liu S, Asparuhova M, Brondani V, et al. Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucl Acids Res 2004; 32: 3752-3759.
16. Asparuhova MB, Marti G, Liu S, et al. Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J Gene Med 2007; 9: 323-334.
17. Colgan J, Asmal M, Luban J. Isolation, Characterization and targeted disruption of mouse Ppia: cyclophilin A is not essential for mammalian cell viability. Genomics 2000; 68: 167-178.
18. Colgan J, Asmal M, Neagu M, et al. Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity 2004; 21: 189-201.
19. Braaten D, Franke EK, Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol 1996; 70: 3551-3560.
20. Saphire AC, Bobardt MD, Gallay PA. Cyclophilin a plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation. J Virol 2002; 76: 4671-4677.
21. Kootstra NA, Munk C, Tonnu N, et al. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. PNAS 2003; 100: 1298-1303.
22. Towers GJ, Hatziioannou T, Cowan S, et al. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003; 9: 1138-1143.
23. Schumperli D, Pillai RS. The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein. Cell Mol Life Sci 2004; 61: 2560-2570.
24. Asparuhova M, Kole R, Schumperli D. Antisense derivatives of U7 and other small nuclear RNAs as tools to modify pre-mRNA splicing patterns. Gene Ther Regul 2004; 2: 321-349.
25. Gorman L, Suter D, Emerick V, et al. Stable alteration of premRNA splicing patterns by modified U7 small nuclear RNAs. PNAS 1998; 95: 4929-4934.
26. Suter D, Tomasini R, Reber U, et al. Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations. Hum Mol Genet 1999; 8: 2415-2423.
27. Brun C, Suter D, Pauli C, et al. U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping. Cell Mol Life Sci 2003; 60: 557-566.
28. Tang H, Kuhen KL, Wong-Staal F. Lentivirus replication and regulation. Annu Rev Genet 1999; 33: 133-170.
29. Chiu YL, Greene WC. Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol 2006; 27: 291-297.
30. Mangeat B, Turelli P, Caron G, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99-103.
31. Lecossier D, Bouchonnet F, Clavel F, et al. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003; 300: 1112.
32. Zhang H, Yang B, Pomerantz RJ, et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424: 94-98.
33. Guo F, Cen S, Niu M, et al. Inhibition of tRNALys-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol 2006; 80: 11710-11722.
34. Newman ENC. Holmes RK, Craig HM, et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005; 15: 166-170.
35. Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 2006; 80: 8450-8458.
36. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
37. Koseki S, Tanabe T, Tani K, et al. Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J Virol 1999; 73: 1868-1877.
38. Ariumi Y, Turelli P, Masutani M, et al. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. The Journal of Virology 2005; 79: 2973-2978.
39. Pillai RS, Grimmler M, Meister G, et al. Unique Smcore structure of U7 snRNPs: assembly by a specialized SMN complex and the role of a new component, Lsm11, in histone RNA processing. Genes Dev 2003; 17: 2321-2333.
40. Ambrosino C, Palmieri C, Puca A, et al. Physical and functional interaction of HIV-1 Tat with E2F-4, a transcriptional regulator of mammalian cell cycle. J Biol Chem 2002; 277: 31448-31458.
41. Hope TJ, Huang X, McDonald D, et al. Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif. PNAS 1990; 87: 7787-7791.
42. Charneau P, Mirambeau G, Roux P, et al. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994; 241: 651-662.
43. Marquis J, Meyer K, Angehrn L, et al. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol Ther 2007; 15: 1479-1486.
44. Zufferey R, Nagy D, Mandel RJ, et al. Multiple attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
45. Akkina RK, Walton RM, Chen ML, et al. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 1996; 70: 2581-585.
46. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
47. von Schwedler U, Song J, Aiken C, et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993; 67: 4945-4955.
48. Trono D, Feinberg MB, Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989; 59: 113-120.
49. Charrier S, Stockholm D, Seye K, et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 2004; 12: 597-606.
50. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
51. Sokolskaja E, Sayah DM, Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 2004; 78: 12800-12808.
52. Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA mediated RNA interference. J Immunol 2002; 169: 5196-5201.
53. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438.
54. Saphire AC, Bobardt MD, Gallay PA. Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO J 1999; 18: 6771-6785.
55. Pushkarsky T, Zybarth G, Dubrovsky L, et al. CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. PNAS 2001; 98: 6360-6365.
56. Yam PY, Li S, Wu J, et al. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 2002; 5: 479-484.